Global insights driving the market strategies of tomorrow.

Allurion (ALUR.US) stock experiences a violent surge as its innovative weight loss therapy effectively maintains muscle mass.

Market IntelFriday, Jan 24, 2025 2:31 am ET

1min read

Allurion (ALUR.US) shares rose more than 21% on Thursday; the stock further soared 80% in after-hours trading after the company said it planned to conduct a clinical study combining its gastric balloon weight loss product with GLP-1 drugs. Allurion announced in the last ten minutes of the market that it was planning a study to evaluate the effect of Allurion's planned GLP-1 drug on improving overall body composition and muscle mass. The company noted that while studies have shown that using GLP-1 can significantly reduce muscle mass, patients treated with Allurion's balloon therapy were able to maintain or even increase muscle mass."Our study aims to prove that patients can significantly lose weight while increasing muscle mass and improving overall body composition by combining Allurion Balloon and Allurion Virtual Care Suite with GLP-1 treatment," said Shantanu Gaur, founder and CEO of Allurion, in a statement.Novo Nordisk's semaglutide and Eli Lilly's tizepatide are both GLP-1 drugs. Novo Nordisk named its diabetes treatment semaglutide Ozempic and its weight loss treatment semaglutide Wegovy; Lilly named its diabetes treatment tizepatide Mounjaro and its weight loss treatment tizepatide Zepbound.Other companies developing GLP-1 drugs include AstraZeneca (AZN.US), Amgen (AMGN.US), Pfizer (PFE.US), Roche, Altimmune (ALT.US), Viking Therapeutics (VKTX.US), Zealand, Terns Pharmaceuticals (TERN.US) and Structure Therapeutics (GPCR.US).

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.